Recombinant Human PD-L1 His Protein
Novus Biologicals, part of Bio-Techne | Catalog # NBP1-98984
Key Product Details
Source
E. coli
Tag
His
Conjugate
Unconjugated
Applications
SDS-PAGE
Product Specifications
Description
A recombinant protein with a N-Terminal His-tag and corresponding to the amino acids 19-238 of Human PD-L1/B7-H1
Source: E.coli
Amino Acid Sequence: MGSSHHHHHH SSGLVPRGSH MGSHMFTVTV PKDLYVVEYG SNMTIECKFP VEKQLDLAAL IVYWEMEDKN IIQFVHGEED LKVQHSSYRQ RARLLKDQLS LGNAALQITD VKLQDAGVYR CMISYGGADY KRITVKVNAP YNKINQRILV VDPVTSEHEL TCQAEGYPKA EVIWTSSDHQ VLSGKTTTTN SKREEKLFNV TSTLRINTTT NEIFYCTFRR LDPEENHTAE LVIPELPLAH PPNER
Purity
>90%, by SDS-PAGE
Predicted Molecular Mass
27.9 kDa.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Protein / Peptide Type
Recombinant Protein
Scientific Data Images for Recombinant Human PD-L1 His Protein
![SDS-PAGE: Recombinant Human PD-L1 His Protein [NBP1-98984]](https://resources.bio-techne.com/images/products/Recombinant-Human-B7-H1-PD-L1-CD274-Protein-SDS-Page-NBP1-98984-img0002.jpg "SDS-PAGE: Recombinant Human PD-L1 His Protein [NBP1-98984]")
SDS-PAGE: Recombinant Human PD-L1 His Protein [NBP1-98984]
SDS-Page: Recombinant Human PD-L1/B7-H1 Protein [NBP1-98984]Formulation, Preparation and Storage
NBP1-98984
| Formulation | 20 mM Tris-HCl buffer (pH8.0), 10% glycerol, 1 mM DTT |
| Preservative | No Preservative |
| Concentration | 1 mg/ml |
| Shipping | The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below. |
| Stability & Storage | Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles. |
Background: PD-L1/B7-H1
PD-L1 binding with receptor PD-1 results in phosphorylation of in the inhibitory tyrosine-based switch motif (ITSM) domain of PD-1, which leads to recruitment of Src homology 2 domain-containing protein tyrosine-phosphatase 2 (SHP-2) and eventual downstream phosphorylation of spleen tyrosine kinase (Syk) and phospholipid inositol-3-kinase (PI3K) (1,3). Under normal conditions, the PD-L1/PD-1 signaling axis helps maintain immune tolerance and prevent destructive immune responses by inhibiting T cell activity such as proliferation, survival, cytokine production, and cytotoxic T lymphocyte (CTL) cytotoxicity (1-3). In the tumor microenvironment (TME), however, the PD-L1/PD-1 signaling axis is hijacked to promote tumor cell survival and limit anti-tumor immune response (1,3). More precisely, tumor cells can escape killing and immune surveillance due to T cell exhaustion and apoptosis (1-3).
Given the role the PD-L1/PD-1 signaling axis plays in tumor cells' ability to evade immune surveillance, it has become a target of several immunotherapeutic agents in recent years (3,5). Antibody immunotherapies that target these inhibitory checkpoint molecules has shown great promise for cancer treatment (3,5). PD-L1 and PD-1 blocking agents have been approved for treatment in a number of cancers including melanoma, non-small cell lung cancer (NSCLC), urothelial carcinoma, and Merkel-cell carcinoma (3,5). In many cancers the expression of PD-L1 in the TME has predictive value for response to blocking agents (3). Pembrolizumab, for example, is a PD-1 inhibitor that has been approved by the FDA as a second-line therapy for treatment of metastatic NSCLC in patients whose tumors express PD-L1 with a Tumor Proportion Score (TPS) greater than 1%, but also for first-line treatment in cases where patients' tumors expression PD-L1 with a TPS greater than 50%) (5). The most promising cancer immunotherapy treatments seem to point to combination therapy with both anti-cancer drugs (e.g. Gefitibin, Metformin, Etoposide) with PD-L1/PD-1 antibody blockade inhibitors (e.g. Atezolizumab, Nivolumab) (6).
References
1. Han, Y., Liu, D., & Li, L. (2020). PD-1/PD-L1 pathway: current researches in cancer. American journal of cancer research, 10(3), 727-742.
2. Jiang, Y., Chen, M., Nie, H., & Yuan, Y. (2019). PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations. Human vaccines & immunotherapeutics, 15(5), 1111-1122. https://doi.org/10.1080/21645515.2019.1571892
3. Sun, C., Mezzadra, R., & Schumacher, T. N. (2018). Regulation and Function of the PD-L1 Checkpoint. Immunity, 48(3), 434-452. https://doi.org/10.1016/j.immuni.2018.03.014
4. Cha, J. H., Chan, L. C., Li, C. W., Hsu, J. L., & Hung, M. C. (2019). Mechanisms Controlling PD-L1 Expression in Cancer. Molecular cell, 76(3), 359-370. https://doi.org/10.1016/j.molcel.2019.09.030
5. Tsoukalas, N., Kiakou, M., Tsapakidis, K., Tolia, M., Aravantinou-Fatorou, E., Baxevanos, P., Kyrgias, G., & Theocharis, S. (2019). PD-1 and PD-L1 as immunotherapy targets and biomarkers in non-small cell lung cancer. Journal of B.U.ON. : official journal of the Balkan Union of Oncology, 24(3), 883-888.
6. Gou, Q., Dong, C., Xu, H., Khan, B., Jin, J., Liu, Q., Shi, J., & Hou, Y. (2020). PD-L1 degradation pathway and immunotherapy for cancer. Cell death & disease, 11(11), 955. https://doi.org/10.1038/s41419-020-03140-2
Long Name
Programmed Death Ligand 1
Alternate Names
B7-H1, B7H1, CD274, PDCD1L1, PDCD1LG1, PDL1
Gene Symbol
CD274
Additional PD-L1/B7-H1 Products
Product Documents for Recombinant Human PD-L1 His Protein
Product Specific Notices for Recombinant Human PD-L1 His Protein
This product is for research use only and is not approved for use in humans or in clinical diagnosis. This product is guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...